Stock XLS XLIFE SCIENCES AG
Add to a list
To use this feature you must be a member
Log inSign up

Xlife Sciences AG Stock BOERSE MUENCHEN

Equities

XLS

CH0461929603

Biotechnology & Medical Research

Market Closed - BOERSE MUENCHEN
Other stock markets
 13:43:00 2022-02-10 EST 		5-day change 1st Jan Change
41.8 EUR -0.48% Intraday chart for Xlife Sciences AG -7.52% -3.69%
04-23 Xlife Sciences Posts Higher FY23 Profit; Revenue Falls MT
02-29 Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 800K 875K 818K 1.2M Sales 2025 * - Capitalization 196M 214M 200M 292M
Net income 2024 * -4M -4.37M -4.09M -5.98M Net income 2025 * - EV / Sales 2024 * 326 x
Net Debt 2024 * 65.2M 71.29M 66.67M 97.44M Net cash position 2025 * - 0 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-52 x
P/E ratio 2025 *
-
Employees 13
Yield 2024 *
-
Yield 2025 *
-
Free-Float 49.77%
More Fundamentals * Assessed data

Chart Xlife Sciences AG

Dynamic Chart

Latest news about Xlife Sciences AG

Xlife Sciences Posts Higher FY23 Profit; Revenue Falls MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership MT
Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection MT
Xlife Sciences to Sell Portfolio Company to 4D Lifetec MT
Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million. CI
Xlife Sciences Loss Narrows in H1; Revenue Declines MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Xlife Sciences AG Signs Memorandum of Understanding with the Regulator of the Healthcare Sector in the UAE, the Department of Health - Abu Dhabi CI
Xlife Sciences AG Announces Bernhard Scholz Will Not Stand for Re-Election CI
Xlife Sciences Posts Lower FY22 EPS; Revenue Increases MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Xlife Sciences Portfolio Company Receives European Patent for Biological Tissue Generation Method MT
Xlife Sciences' Portfolio Company To Research Therapy For Amyotrophic Lateral Sclerosis MT
Xlife Sciences AG Launches Project to Research a Potential Therapy for Amyotrophic Lateral Sclerosis CI
More news

Press releases Xlife Sciences AG

Xlife Sciences AG Publishes 2023 Annual Report EQ
Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland EQ
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City EQ
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline EQ
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases EQ
More press releases

News in other languages on Xlife Sciences AG

Bourse Zurich: séance positive, le SMI proche des 11'500 points
Xlife Sciences a vu son bénéfice progresser en 2023
XLife Sciences 2023 mit stabiler Entwicklung
Xlife Sciences AG veröffentlicht Geschäftsbericht 2023
Xlife Sciences AG veröffentlicht Geschäftsbericht 2023
More news

Quotes and Performance

1 day-0.48%
Current month-3.69%
Current year-3.69%
More quotes

Highs and lows

3 years
41.80
Extreme 41.8
60.00
5 years
24.00
Extreme 24
60.00
10 years
24.00
Extreme 24
60.00
More quotes

Managers and Directors - Xlife Sciences AG

Managers TitleAgeSince
Oliver Baumann CEO
 Chief Executive Officer - 19-06-30
Carl von Halem DFI
 Director of Finance/CFO - 21-11-30
Alexander Zink CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Christian Faber CMP
 Compliance Officer - 19-09-11
Mark Müller BRD
 Director/Board Member - 18-10-24
Oliver Baumann CEO
 Chief Executive Officer - 19-06-30
More insiders

Company Profile

Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.
Sector
Biotechnology & Medical Research
Calendar
2024-06-27 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Xlife Sciences AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
34.3 CHF
Average target price
68 CHF
Spread / Average Target
+98.25%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XLS Stock
  4. XLS Stock